Log In
Print this Print this

BMN 701 (formerly ZC-701)

  Manage Alerts
Collapse Summary General Information
Company BioMarin Pharmaceutical Inc.
DescriptionFusion of insulin-like growth factor-2 (IGF-2) and acid alpha glucosidase (GAA) that uses Glycosylation Independent Lysosomal Targeting (GILT) technology
Molecular Target Insulin-like growth factor-2 (IGF-2) receptor (IGF2R) (M6PR)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase III
Standard IndicationPompe's disease
Indication DetailsTreat late-onset Pompe's disease; Treat Pompe's disease
Regulatory Designation U.S. - Orphan Drug (Treat Pompe's disease)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today